9 November 2017 in Lab on a Chip
We developed a microfluidic approach to simultaneously incorporate various catalysts into the micromotor in a one-step process. This provides the micromotor with self-propelled, magnetic and water treatment functions, which should benefit a wide range of applications.
15 January 2024 in Lab on a Chip
Microfluidic-enabled smart microcapsules as delivery systems from droplet fabrication to tailored delivery and controlled release.
1 February 2022 in Nanoscale
We present a machine learning approach-based array sensor for high-accuracy profiling of mechanisms of action (MoAs) by sensing the physicochemical changes on surfaces of bacteria. We successfully predict the MoAs of 4 antimicrobial compounds and a novel small molecule AMP.
25 December 2021 in Bioactive Materials
In-situ oral delivery of therapeutic antibodies, like monoclonal antibody, for chronic inflammation treatment is the most convenient approach compared with other administration routes. Moreover, the abundant links between the gut microbiota and colonic inflammation indicate that the synergistic or antagonistic effect of gut microbiota to colonic inflammation. However, the antibody activity would be significantly affected while transferring through the gastrointestinal tract due to hostile conditions. Moreover, these antibodies have short serum half-lives, thus, require to be frequently administered with high doses to be effective, leading to low patient tolerance. Here, we develop a strategy utilizing thin shell hydrogel microcapsule fabricated by microfluidic technique as the oral delivering carrier. By encapsulating antibodies in these microcapsules, antibodies survive in the hostile gastrointestinal environment and rapidly release into the small intestine through oral administration route, achieving the same therapeutic effect as the intravenous injection evaluated by a colonic inflammation disease model. Moreover, the abundance of some intestinal microorganisms as the indication of the improvement of inflammation has remarkably altered after in-situ antibody-laden microcapsules delivery, implying the restoration of micro-ecology of the intestine. These findings prove our microcapsules are exploited as an efficient oral delivery agent for antibodies with programmable function in clinical application.